Investors faced disappointment as HLS Therapeutics Inc experienced a notable decline in its stock price.
HLS Therapeutics Inc (HLS.TO) saw its stock price drop by 2.30% in yesterday's trading session, closing at CA$3.83. This decline reflects ongoing challenges in the market and investor sentiment towards the company's recent performance.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$122.60M
52W high
$5.76
52W low
$3.81
1W change
-7.04%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 88.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.21
+88.4% Upside
Current Price
C$3.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
28.7%
Annualized
90-Day Vol
24.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.20
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.61 | C$3.27 – C$3.98 |
| 60 trading days | C$3.40 | C$2.96 – C$3.91 |
| 90 trading days | C$3.20 | C$2.70 – C$3.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The drop in HLS Therapeutics' stock price highlights the volatility in the pharmaceutical sector, where even small fluctuations can significantly impact investor confidence.
HLS Therapeutics Inc Market Cap
The company's market cap stands at CA$119.78 million, reflecting investor caution amidst fluctuating stock performance.
Bull case
Despite the recent decline, HLS Therapeutics has reported a 2% year-over-year revenue increase in Q1 2026. This suggests there’s potential for growth in the long term, which could be a positive sign for investors looking ahead.
Bear case
On the flip side, the negative sentiment surrounding HLS Therapeutics could be worsened by its ongoing struggles with profitability. The company has a profit margin of -0.1846, which raises concerns about its financial stability and ability to attract investors.
Stock Performance Overview
Advertisement
HLS Therapeutics Inc's stock performance yesterday reflected investor caution, with a notable drop of 2.30%. The closing price of CA$3.83 raises questions about the company's market position, especially in light of its recent financial results.
Financial Health and Market Sentiment
The company's financial health remains a concern, as shown by its profit margin of -0.1846. While there was a slight increase in revenue, investor sentiment seems to be influenced by broader market dynamics and the company's ongoing challenges. For more insights, check out the latest Q1 2026 Financial Results.
Looking Ahead
As HLS Therapeutics navigates its current challenges, investors will be keen to see how the company addresses its profitability issues. The launch of new products like NILEMDO™ may provide some optimism, but the market's reaction will ultimately depend on sustained performance. For further details, visit the HLS stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
